<DOC>
	<DOCNO>NCT03059719</DOCNO>
	<brief_summary>This randomize , open , positive drug-controlled ( Exenatide , Byetta ) , sequential parallel group , multiple dose study evaluate safety , tolerability , pharmacokinetics pharmacodynamics twelve once-weekly subcutaneous dos PB-119 subject type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Clinical Trial PB-119 Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>There two study phase accord different dos investigational drug Phase 1：1 investigational group 1 control group , i.e . ; investigational drug PB-119 injection 25µg group control drug exenatide group . Phase 1： Plan 1 2 investigational group accord study result phase 1 , i.e. , investigational drug PB-119 injection 50 µg group control drug exenatide group . Subject Number：18 subject randomize group , equal number female male . 12 subject PB-119 group , 6 subject exenatide group .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>1 . Male and/or female subject age 18~45 ( inclusive ) year , ratio female male approximately 1:1 ; 2 . Subject disguise type 2 diabetes within 5 year screen , meet diagnosis criterion type 2 diabetes guidance WHO Chinese Diabetes Society ( CDS ) ; 3 . Subject n't receive treatment diabetes screen , subject diet control 3 month , Fasting Plasma Glucose ( FPG ) 7.0 ~ 13.0 mmol / L ( include boundary value ) , glycosylated hemoglobin ( HbA1c ) 7.0 % ~ 10 % ( Including boundary value ) ; 4 . Female weight ≥45 kg , male weight ≥50 kg , subject body mass index ( BMI ) 19~30 kg/m2 ( inclusive ) ; 5 . Subject understand procedure method clinical trial , willing participate sign write informed consent ; 1 . Subject diagnose type 1 diabetes 2 . Subject acute complication diabetes , ketoacidosis hyperosmolar coma within 6 month screen ; 3 . Subject allergic exenatide , investigational drug ingredient ( citric acid , mannitol , mcresol ) ; specific severe drug allergy history 4 . Patient specific cardiovascular disease , unstable angina pectoris , myocardial infarction , hypertension poor control use one antihypertensive drug ( mean sit systolic blood pressure ≥ 160mmHg diastolic blood pressure ≥ 95mmHg ) , severe arrhythmia , QTc Prolonged , cardiac dysfunction ; 5 . Subject liver kidney dysfunction ( ALT AST &gt; 2 time upper limit normal reference range , TBIL &gt; 1.5 time upper limit normal reference range , Cr &gt; upper limit normal reference range ) ; 6 . Subject 's triglyceride≥5mmol/L； 7 . Subject acute chronic hepatitis , liver disease 8 . Known medical history acute pancreatitis chronic pancreatitis , pancreatic amylase &gt; upper limit normal reference range , serum lipase &gt; upper limit normal reference range ; 9 . Subject disease may impact gastric emptying , gastroparesis , gastric outlet obstruction , intestinal obstruction , receive gastric bypass surgery , longterm use drug may direct impact gastrointestinal peristalsis ; 10 . Subject clinical significant major disease history medical history respiratory system , digestive system , nervous system , hematology system , urology system , immunology , psychiatric system metabolic disorder etc . 11 . Subject liver , kidney gastrointestinal partial resection surgery 12 . Subject drug abuse alcoholic 13 . Subject receive Chinese western medication treatment diabetes ; 14 . Subject take prescription overthecounter medication ( orlistat , sibutramine , rimonabant , phenylpropanol chlorpheniramine ) promote weight loss within 3 month study ; 15 . Take medication may affect test result , antibiotic , nonsteroidal antiinflammatory drug , antacid contain aluminum magnesium , diuretic , anticoagulant , central nervous system inhibitor , systemic corticosteroid , medication slow gastrointestinal motility , drug may possibly affect absorption drug within 2 week screen ; 16 . Participated clinical trial within 3 month trial ; 17 . Female pregnant lactating ; 18 . Subject able use contraceptive method medically recognize study ; 19 . Subject complete study due reason determine investigator inappropriate participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>